Leo Rasche
About
Leo Rasche is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Leo Rasche has authored 140 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Hematology, 83 papers in Oncology and 62 papers in Molecular Biology. Recurrent topics in Leo Rasche's work include Multiple Myeloma Research and Treatments (102 papers), Protein Degradation and Inhibitors (36 papers) and CAR-T cell therapy research (32 papers). Leo Rasche is often cited by papers focused on Multiple Myeloma Research and Treatments (102 papers), Protein Degradation and Inhibitors (36 papers) and CAR-T cell therapy research (32 papers). Leo Rasche collaborates with scholars based in Germany, United States and Spain. Leo Rasche's co-authors include Hermann Einsele, Niels Weinhold, K. Martin Kortüm, Johannes Duell, Andreas Rosenwald, Max S. Topp, Gareth J. Morgan, Stefan Knop, Markus Kapp and Stephan Mielke and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.
In The Last Decade
Leo Rasche
122 papers receiving 2.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Leo Rasche Germany | 29 | 1.3k | 1.3k | 1.1k | 394 | 368 | 140 | 2.3k | ||
| XG Zhang China | 16 | 964 0.7× | 1.2k 0.9× | 892 0.8× | 586 1.5× | 221 0.6× | 40 | 2.2k | ||
| Hang Quach Australia | 23 | 1.4k 1.0× | 1.8k 1.4× | 1.4k 1.3× | 534 1.4× | 235 0.6× | 209 | 2.6k | ||
| Paula Rodríguez‐Otero Spain | 29 | 1.7k 1.3× | 2.0k 1.6× | 1.7k 1.6× | 621 1.6× | 576 1.6× | 181 | 3.4k | ||
| Hareth Nahi Sweden | 30 | 1.5k 1.2× | 2.0k 1.6× | 1.6k 1.5× | 559 1.4× | 291 0.8× | 143 | 3.0k | ||
| Steven Limentani United States | 25 | 2.0k 1.6× | 1.1k 0.9× | 1.3k 1.2× | 142 0.4× | 641 1.7× | 60 | 3.4k | ||
| Yvonne A. Efebera United States | 27 | 1.6k 1.2× | 1.4k 1.1× | 1.0k 1.0× | 1.4k 3.5× | 185 0.5× | 150 | 3.0k | ||
| Christoph Heuck United States | 23 | 851 0.7× | 1.3k 1.0× | 1.1k 1.0× | 413 1.0× | 176 0.5× | 101 | 2.1k | ||
| Alejandro Martı́n Spain | 25 | 1.4k 1.1× | 909 0.7× | 845 0.8× | 465 1.2× | 183 0.5× | 128 | 2.8k | ||
| Cyrille Touzeau France | 29 | 1.5k 1.1× | 1.8k 1.4× | 1.6k 1.5× | 320 0.8× | 333 0.9× | 204 | 3.0k | ||
| Rakesh Popat United Kingdom | 29 | 1.4k 1.1× | 1.9k 1.5× | 1.7k 1.6× | 199 0.5× | 410 1.1× | 154 | 2.7k |
Countries citing papers authored by Leo Rasche
Since
Specialization
Citations
This map shows the geographic impact of Leo Rasche's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo Rasche with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo Rasche more than expected).
Fields of papers citing papers by Leo Rasche
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Leo Rasche. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo Rasche. The network helps show where Leo Rasche may publish in the future.
Co-authorship network of co-authors of Leo Rasche
This figure shows the co-authorship network connecting the top 25 collaborators of Leo Rasche. A scholar is included among the top collaborators of Leo Rasche based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo Rasche. Leo Rasche is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Roll, M., Götz Gelbrich, Johannes M. Waldschmidt, et al.. (2025). Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan. Cancer Medicine. 14(23). e71401–e71401.
2.
Schinke, Carolina, Leo Rasche, Marc S. Raab, & Niels Weinhold. (2024). Impact of Clonal Heterogeneity in Multiple Myeloma. Hematology/Oncology Clinics of North America. 38(2). 461–476.
3.
Duell, Johannes, et al.. (2024). Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies. Journal for ImmunoTherapy of Cancer. 12(12). e009174–e009174.
4.
Waldschmidt, Johannes M. & Leo Rasche. (2024). BCMA bispecifics: breaking the chains of resistance. Blood. 144(25). 2566–2568.
5.
Leypoldt, Lisa, Xiang Zhou, Winfried Alsdorf, et al.. (2024). Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement. Blood. 144(Supplement 1). 3792.4–3792.4.
6.
Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S240–S240.
7.
Schinke, Carolina, Cyrille Touzeau, Monique C. Minnema, et al.. (2024). P-098 Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S99.
8.
Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S561–S562.
9.
Danhof, Sophia, Xiang Zhou, Georg Fette, et al.. (2024). Real-World Confirmatory Analysis of the Current IMWG Diagnostic Criteria Identifies Early Transformation As Major Risk Factor in Plasma Cell Leukemia. Blood. 144(Supplement 1). 6893–6893.
10.
Duell, Johannes, Alexander M. Leipold, Silke Appenzeller, et al.. (2023). Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy. Blood. 143(8). 685–696.
11.
Zhou, Xiang, Lukas Scheller, Johannes M. Waldschmidt, et al.. (2023). Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study. Blood. 142(Supplement 1). 95–95.
12.
Vogt, Cornelia, Larissa Haertle, Xiang Zhou, et al.. (2023). Secondary Genetic Events Impact the Expression of Key Immunotargets on the Surface of Multiple Myeloma Cells. Blood. 142(Supplement 1). 451–451.
13.
Schürch, Christian M., Leo Rasche, Leonie Frauenfeld, Niels Weinhold, & Falko Fend. (2019). A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 476(3). 337–351.
14.
Danhof, Sophia, Martin Schreder, Antonio Giovanni Solimando, et al.. (2019). Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research. Journal of Clinical Medicine. 8(7). 999–999.
15.
Ashby, Cody, Michael Bauer, Owen Stephens, et al.. (2017). Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots within the Non-Coding Regions. Blood. 130. 3032.
16.
Thanendrarajan, Sharmilan, Carolina Schinke, Frits van Rhee, et al.. (2017). Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma. Blood. 130. 1858–1858.
17.
Rasche, Leo, Carolina Schinke, Daisy Alapat, et al.. (2017). Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse. Blood. 130. 4510–4510.
18.
Rasche, Leo, Emmanuelle Ménoret, Valentina Dubljevic, et al.. (2016). A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement. Clinical Cancer Research. 22(17). 4341–4349.
19.
Danhof, Sophia, Martin Schreder, Leo Rasche, et al.. (2015). ‘Real‐life’ experience of preapproval carfilzomib‐based therapy in myeloma – analysis of cardiac toxicity and predisposing factors. European Journal Of Haematology. 97(1). 25–32.
20.
Numanoğlu, Alp, et al.. (2008). Laparoscopic Insertion with Tip Suturing, Omentectomy, and Ovariopexy Improves Lifespan of Peritoneal Dialysis Catheters in Children. Journal of Laparoendoscopic & Advanced Surgical Techniques. 18(2). 302–305.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by XG Zhang Breakdown of academic impact, for papers by Hang Quach Breakdown of academic impact, for papers by Paula Rodríguez‐Otero Breakdown of academic impact, for papers by Hareth Nahi Breakdown of academic impact, for papers by Steven Limentani Breakdown of academic impact, for papers by Yvonne A. Efebera Breakdown of academic impact, for papers by Christoph Heuck Breakdown of academic impact, for papers by Alejandro Martı́n Breakdown of academic impact, for papers by Cyrille Touzeau Breakdown of academic impact, for papers by Rakesh Popat